ORGO vs RCEL
ORGO: Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates and FDA regulatory compliance. RCEL: A therapeutic wound care company commercializing RECELL, an autologous cell harvesting device that creates patient-derived skin cell suspension for treating burns and traumatic injuries, now expanding into a multi-product acute wound care platform.
Side-by-side fundamentals
| Metric | ORGO | RCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.47 | $4.94 | |
| Market cap as of 2026-07-23 | $311M | $157M | |
| P/E as of 2026-07-23 | 114.52 | n/a | |
| PEG as of 2026-07-23 | -2.62 | n/a | |
| Net margin as of 2026-07-23 | +0.5% | -62.7% | ORGO higher |
| Gross margin as of 2026-07-23 | +72.9% | +82.1% | RCEL higher |
| Operating margin as of 2026-07-23 | +0.5% | -54.6% | ORGO higher |
| ROE as of 2026-07-23 | +0.7% | -337.9% | ORGO higher |
| ROA as of 2026-07-23 | +0.5% | -78.9% | ORGO higher |
| Debt / equity as of 2026-07-23 | 0.03 | 9.39 | ORGO lower |
| Revenue growth (YoY) as of 2026-07-23 | +12.2% | +1.0% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | +7.8% | +27.7% | RCEL higher |
| Beta as of 2026-07-23 | 1.34 | 1.84 | |
| 1-year return as of 2026-07-22 close | -48.8% | -15.0% | RCEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.